Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, Inc. (MYO) common shares are the subject of an amended ownership report by Rosalind Advisors, Inc., Rosalind Master Fund L.P. (RMF), portfolio manager Steven Salamon and reporting person Gilad Aharon. The cover pages list 7,681,144 shares as aggregate beneficially owned, including 3,917,886 common shares and 3,763,258 shares issuable upon exercise of pre-funded warrants; the reported aggregate does not give effect to warrant blockers.
RMF states its 3,917,886 common shares represent approximately 9.77% of the common stock, using 40,099,174 shares outstanding as of November 3, 2026. The reporting persons said no warrants could be exercised as of September 30, 2026, because of a blocker limiting exercise that would result in beneficial ownership above 9.99%. Rosalind Advisors and Salamon disclaim beneficial ownership.
Myomo, Inc. (MYO) reported third-quarter revenue of $12.33 million, up from $10.09 million a year earlier, with gross margin rising to 71.3% from 63.8%. Net loss widened to $4.23 million from $3.66 million; other expense included $1.85 million in losses from fair-value changes in derivative liabilities.
For the first nine months, revenue was $34.15 million versus $29.57 million; net loss was $11.26 million versus $11.76 million, and operating cash use was $5.45 million versus $13.37 million. At September 30, 2026, cash, cash equivalents and short-term investments totaled $11.95 million. Myomo believes these resources and expected cash flows can fund operations for at least 12 months. Its loan agreement provides for up to $17.5 million in committed term loans, including $12.5 million funded.
Myomo said it notified the parties on July 24, 2026, that it was terminating its China joint venture. The company expects no liquidation proceeds and reported no financial-statement impact for the three- or nine-month periods.
Myomo, Inc. reported third-quarter 2026 revenue of $12.3 million, up 22% year over year, and gross margin of 71.3%, compared with 63.8%. Recurring patient sources accounted for 54% of revenue, versus 33% a year earlier, and the company recorded 258 orders, up 13% year over year.
Operating expenses increased 6% to $10.5 million, while operating loss was $1.7 million versus $3.5 million a year earlier. The company described Adjusted EBITDA as breakeven; its reconciliation lists a loss of $1,513, compared with a loss of $2.7 million. Net loss was $4.2 million, including a $1.8 million noncash charge related to the fair value of derivative liabilities, versus $3.7 million.
Myomo updated its full-year 2026 revenue guidance to $46 million-$47 million, describing it as the upper half of the prior range, and continued to expect second-half cash burn below $2 million. Cash, cash equivalents and short-term investments totaled $11.9 million as of September 30, 2026; operating cash use was $1.3 million for the quarter, compared with $1.8 million a year earlier. MyoConnect referrals have come from more than 500 rehabilitation facilities and therapy centers.
Myomo, Inc. Chief Medical Officer Harry Kovelman received a grant of 32,500 restricted stock units on October 13, 2026. The RSUs vest in three equal annual installments beginning June 9, 2027; his reported direct holdings after the transaction were 122,389 shares.
MYOMO, Inc. Chief Medical Officer Harry Kovelman sold 15,844 shares of common stock on September 11, 2026, at an average price of $1.2709 per share. The sales occurred in multiple lots at prices ranging from $1.25 to $1.29 per share. His reported direct holdings afterward were 89,889 shares. The amendment corrects a transposition error in the number of shares sold and the resulting beneficial ownership; no Rule 10b5-1 plan is reported.
Myomo, Inc. Chief Financial Officer David A. Henry acquired 51,250 restricted stock units on October 13, 2026, as a grant under the company's 2018 Stock Option and Incentive Plan. His reported direct holdings following the award were 549,862 shares. The units vest in three equal annual installments beginning June 9, 2027; this was an award, not a market purchase.
MYOMO, Inc. Chief Executive Officer and director Paul R. Gudonis received a grant of 71,250 restricted stock units on October 13, 2026, under the company's 2018 Stock Option and Incentive Plan. His reported direct common stock holdings following the transaction were 1,514,292 shares.
Myomo, Inc. Chief Financial Officer David A. Henry received a grant of 6,272 restricted stock units on October 9, 2026, through a program in which employees forego 10% of salary for RSUs with a grant-date fair value of 115% of the salary exchanged. The grant covers three months of salary and vests in full on January 9, 2027. Separately, Henry sold 3,133 common shares at $1.37 per share on October 12, 2026, solely to pay income and other taxes associated with RSUs vesting October 8, 2026, pursuant to an irrevocable election made December 11, 2025. No Rule 10b5-1 plan is reported.
Chief Executive Officer and director Paul R. Gudonis received a direct award of 8,363 shares of Myomo, Inc. common stock on October 9, 2026. His reported direct holdings following the award were 1,443,042 shares. The Restricted Stock Units vest in full on January 9, 2027.
Myomo, Inc. (MYO) officer David Henry reported plans to sell 3,133 common shares on October 12, 2026, through Morgan Stanley. He says the shares are being sold solely to pay income taxes on restricted stock units vesting October 8, 2026, under an irrevocable election made December 11, 2025. Henry also reported selling 5,166 shares on July 13, 2026, for gross proceeds of $5,682.60.